Plain-English translation of NCT06980025 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This study is testing whether aspirin at a higher dose (162 mg daily) works better than a lower dose (81 mg daily) to prevent early delivery in pregnant people who have experienced premature birth before. Researchers will follow 1,800 pregnant participants starting around 10–15 weeks of pregnancy through delivery to see which dose is more effective at reducing the risk of another early delivery.
Many pregnant people who have had an early delivery are at high risk for it happening again. Doctors want to find the best dose of this medication to safely protect these pregnancies and help babies stay in the womb longer.
You likely qualify if…
You likely don't qualify if…
You will take one or two aspirin capsules by mouth every day from about 10–15 weeks of pregnancy until 36 weeks. You'll have monthly check-ins (either in person or by video) where staff will ask about side effects, other medications, and any hospital visits. After delivery, researchers will collect information about your pregnancy and your baby's health from your medical records.
AI-generated summary from trial data · Aug 20, 2026 · Not medical advice
United States